Biosimilar pharmaceuticals

NHS England to save £300m after patent expiry of most costly drug

By replacing adalimumab with biosimilar versions, NHS hospitals will only pay a quarter of the £400m they currently spend each year on the drug.

Simon Stevens, chief executive of NHS England


Simon Stevens, chief executive of NHS England, said: “By working with patients and front-line clinicians we’ve now successfully negotiated the biggest ever set of savings on what was the NHS’s most costly drug”

The NHS in England will save £300m from the patent expiry of adalimumab, the most costly drug used in NHS hospitals, which is double previous estimates, NHS England has announced.

Adalimumab (Humira; AbbVie) came off patent on 16 October 2018 and is used to treat conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

It was anticipated that biosimilar versions of adalimumab would be made available to NHS patients from December 2018, with savings for the NHS estimated at £150m per year by 2021.

But deals negotiated by NHS England with five manufacturers of adalimumab biosimilars mean the NHS is now set to save £300m — which it says is enough to pay for 11,700 more community nurses or 19,800 more breast cancer treatments for patients.

The deal with the five manufacturers, including the manufacturer of the originator medicine, AbbVie, means that hospitals will only have to pay a quarter of the more than £400m they currently spend each year on adalimumab.

The news also means that NHS England is on course to deliver on its ambition to cut between £200m and £300m from England’s annual medicines bill by 2021 through greater use of best value biological medicines, a year early.

Simon Stevens, chief executive of NHS England, said: “Harnessing the power of competition between drug companies, NHS England has now freed up hundreds of millions of pounds of savings to reinvest in patient care. By working with patients and front-line clinicians we’ve now successfully negotiated the biggest ever set of savings on what was the NHS’s most costly drug.”

More than 46,000 patients in England are currently prescribed adalimumab for severe hospital treated conditions, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

Biosimilar versions are expected to be made available to NHS patients across England in December 2018, although use of the originator may also continue where clinically appropriate or where it is the best value.

Citation: The Salvadore DOI: 10.1211/PJ.2018.20205807

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

  • Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

  • Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

  • Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Jobs you might like

  • Camberley Drive in Liverpool L25 9PU and Mosley Street in Blackburn BB2 3RX

  • Newton Aycliffe, Durham

  • Nottingham, Nottinghamshire

  • Clitheroe, Lancashire

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

левитра харьков

дапоксетин львов